Exposure to radiation from imaging equipment is constantly subjected to scrutiny from regulatory authorities. Ultrasound poses no radiation threat and is constantly further developed to accentuate primary and secondary diagnosis. The next wave in ultrasound technology will witness advancements in Elastography and Contrast Enhanced Ultrasound (CEUS) for diagnosis. High intensity focused ultrasound (HIFU) is also emerging to treat pathologies that usually require surgical intervention.
In its upcoming web conference taking place on Thursday, 4th March 2010, at 3 p.m. GMT Frost & Sullivan will focus on the Next Generation Ultrasound Market in Europe. Research Analyst, Shriram Shanmugham, will present an analysis of advancements such as High Intensity Focused Ultrasound for therapy and contrast enhanced ultrasound for diagnosis.
To participate in this complimentary briefing, please email Katja Feick at [email protected] with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.
This briefing will benefit product managers, R&D/product development engineers, vice presidents for R&D, and CEOs who intend to acquire smaller companies with a viable technology application. Many of the therapeutic ultrasound companies are financed by venture capitals, and this briefing will therefore benefit other VCs interested in investing in the ultrasound sector in the long term.
"Affordability, mobility, cost and no safety threats are factors that make ultrasound a worthy proposition for investment in hospitals," concludes Mr. Shanmugham. "While the market for ultrasound is mature, advancements in technology that address both diagnosis and therapy will trigger a niche sector for growth in the ultrasound market over the next seven to ten years."
Comparing CEUS imaging features in patients with hepatic lymphoepithelioma-like carcinoma and HCC